BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region

Delineation of commonly deleted chromosomal regions in meningiomas by high‐density single nucleotide polymorphism genotyping arrays

“…In line with this hypothesis, only a fraction of all cases with complex karyotypes showed monosomy 22 or del(22q), and cases with multiple chromosomal gains in the absence of other alterations were also identified among this latter subgroup of meningiomas. Apart from the alterations described, it had to be emphasized that in contrast to what occurs in malignant tumors including gliomas (Bergamaschi et al, 2008;Kuga et al, 2008;Konecny et al, 2009;Marx et al, 2009), our results demonstrate that cnLOH as well as gene amplification are either rare or absent in histologically benign meningiomas (Ueki et al, 1999;Wozniak, 2008). These results confirm and extend on previous observations, which indicate that despite tetraploidization may frequently occur in meningiomas, it is usually a secondary event which involves a minor fraction of all cells within a tumor.…”

“…Other candidate cancer-associated genes mapping in the deleted region of chromosome 22 included the CHEK2, EP300, and PPARA genes related to the TP53 pathway (Morimura, 2006;Chrisanthar et al, 2008;Teufel DP, 2009), and the PARVG gene associated with cell adhesion (Olski et al, 2001;Yoshimi et al, 2006). Previous studies suggest the existence of LOH involving small regions of chromosome 22, which are missed by microsatellite mapping, presumably because of their relatively low density (Ueki et al, 1999;Wozniak, 2008), but this could not be confirmed in our study by high-density SNP arrays.…”

Advances in meningioma therapy

“…Despite evaluation of many candidates, such a gene has yet to be identifi ed [4]. A recent study using LOH analysis and realtime polymerase chain reaction identifi ed BCR, which has some functional similarities with NF2, as a candidate tumor suppressor gene [12].…”

Genomic and Expression Alterations of Tumor Suppressor Genes in Meningioma Development, Progression and Recurrence

“…It has appeared to be downregulated in meningiomas with loss of heterozygosity of 22q. The BCR gene is an extremely interesting tumor suppressor candidate, since NF2 and BCR proteins perform similar functions (Wozniak, Piaskowski et al 2008). BCR contains a serine/threonine kinase that functions as a GTPase-activating protein for p21.…”

“…BCR contains a serine/threonine kinase that functions as a GTPase-activating protein for p21. The inactivation of BCR as well as NF2 might lead to hyperactivation of RAC pathway, and together with the downregulation of the gene, suggest that BCR can be considered as a tumor suppressor candidate (Wozniak, Piaskowski et al 2008). Matrix metalloproteinases (MMPs) are proteases capable of degrading extracellular matrix proteins.…”